BioCentury
ARTICLE | Clinical News

DB1038: Ph I started

February 24, 2017 2:19 AM UTC

Dauntless began a crossover, U.S. Phase I trial to compare intranasal DP1038 vs. subcutaneous Sandostatin octreotide acetate in about 32 healthy volunteers. Dauntless is developing DP1038 under sectio...

BCIQ Company Profiles

Dauntless Pharmaceuticals Inc.

BCIQ Target Profiles

Growth hormone receptor